The selection of radiotherapy strategy for high-grade gliomas treatment
https://doi.org/10.17650/1683-3295-2013-0-4-26-32
Abstract
Objective. To reveal the prognostic significant factors, influencing on selection of radiotherapy strategy for treatment of high-grade gliomas. Material and methods. We treated 475 patients with confirmed high-grade gliomas (grade 3-4) in our Russian Scientific Center of Roentgenoradiology (RSCRR) from 01.01.2005 till 31.12.2012. The grade 3 gliomas were diagnosed at 130 (27,4%) patients, grade 4 gliomas - at 345 (72,6%) patients. The main criteria for development of specific treatment program were pathology report data, functional condition of patients (Karnofsky index) and patient’s age - those factors in the base of RPA model and it modified adapted analog developed in Russian Scientific Center of Roentgenoradiology (RSCRR model). Results. The usage of ordinary fractionation mode was the most effective in the group of patients with I-IV grade levels based on modified RSCRR model, while the usage of moderate fractionation mode (3 Gy) is possible at patients of V grade level. The radiotherapy at patients of V grade level according RSCRR model must be conducted within 4-6 weeks after surgical removal of tumor. The radical total boost dose directly influences on patients’ overall survival according to our investigations. The combined chemoradiation therapy in this group of patients doesn’t improve this effectiveness measure of specific treatment. Conclusion. The more accurate criteria for selection of optimal modes of radiation dose fractionation will be defined taking into account the further development and improvement of methodological aspects in realization of radiotherapy for high-grade gliomas treatment.
About the Authors
T. R. Izmailov
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Russian Federation
Russian Federation
G. A. Pan’Shin
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Russian Federation
Russian Federation
P. V. Dacenko
ФГБУ «Российский научный центр рентгенорадиологии» Министерства здравоохранения РФ
Russian Federation
Russian Federation
References
1. Измайлов Т.Р., Даценко П.В., Паньшин Г.А. Адаптированный вариант классификации RPA при лечении глиом высокой степени злокачественности (часть 1) // http://vestnik.rncrr.ru/vestnik/v11/papers/izmt_v11.htm
2. Измайлов Т.Р., Даценко П.В., Паньшин Г.А. Адаптированный вариант классификации RPA при лечении глиом высокой степени злокачественности (часть 2) // http://vestnik.rncrr.ru/vestnik/v11/papers/izmp2_v11.htm
3. Паньшин Г.А., Даценко П.В., Измаилов Т.Р. Высокодозная лучевая терапия глиом головного мозга (под ред. член-корр. РАМН, профессора В.А. Солодкого). Регистрационное удостоверение на медицинскую технологию ФС № 2011/082 от 12.05.11г.
4. Паньшин Г.А., Измайлов Т.Р. Новые режимы лучевой терапии злокачественных опухолей головного мозга (под ред.акад. РАМН, проф. В.П. Харченко) // Регистрационное удостоверение на медицинскую технологию ФС№ 2009/147 от 11.06.09г.
5. Annals of Oncology 21. 2010. v190-v193. doi: 10.1093
6. Dhermain F., de Crevoisier R., Parker F. et al. Role of radiotherapy in recurrent gliomas. Bull Cancer. 2004 Nov; 91(11): 883-9 [Article in French].
7. Ernst-Stecken A., Ganslandt O., Lambrecht U. et al. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007 Feb; 81(3): 287-94.
8. Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma // Clin. Cancer Res. 2000. Vol. 6. P. 2585-2597.
9. Grosu A.L., Kortmann R.D. Radiotherapy of brain tumors. New techniques and treatment strategies for. Nervenarzt. 2010 Aug; 81(8): 918, 920-4, 926-7 [Article in German].
10. Grosu A.L., Weber W.A., Franz M. et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/ CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Oct 1; 63(2): 511-9.
11. NCCN Guidelines/version 1/2012 // http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
12. Nieder C., Mehta M.P. Advances in translational research provide a rationale for clinical re-evaluation of highdose radiotherapy for glioblastoma. Med Hypotheses. 2011 Mar; 76(3): 410-3.
13. Reifenberger J., Reifenberger G., Liu L. et al.Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994, 145: P. 1175- 1190.
14. Roberge D., Souhami L., Olivier A. et al. Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up. Technol Cancer Res Treat. 2006 Feb; 5(1). P. 1-8.
15. Shaw E., Seiferheld, Scott et al. (2003). «Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients». International Journal of Radiation Oncology Biology Physics, 2003, v. 57. 135-6.
16. Tanaka Y., Fujii M., Saito T. et al. Radiation therapy for brain tumors Nippon Igaku Hoshasen Gakkai Zasshi. 2004 Sep; 64(7): S387-393 [Article in Japanese].
Review
For citations:
Izmailov T.R., Pan’Shin G.A., Dacenko P.V. The selection of radiotherapy strategy for high-grade gliomas treatment. Russian journal of neurosurgery. 2013;(4):26-32. (In Russ.) https://doi.org/10.17650/1683-3295-2013-0-4-26-32
Views:
599
Email this article 